839 related articles for article (PubMed ID: 29861433)
21. Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats.
Wang Q; Zuo XR; Wang YY; Xie WP; Wang H; Zhang M
Vascul Pharmacol; 2013 Jan; 58(1-2):71-7. PubMed ID: 22846229
[TBL] [Abstract][Full Text] [Related]
22. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
23. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
24. Hepcidin protects pulmonary artery hypertension in rats by activating NF-κB/TNF-α pathway.
Liu WY; Wang L; Lai YF
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7573-7581. PubMed ID: 31539149
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration.
Bueno-Beti C; Sassi Y; Hajjar RJ; Hadri L
Methods Mol Biol; 2018; 1816():233-241. PubMed ID: 29987824
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats.
Tang C; Luo Y; Li S; Huang B; Xu S; Li L
Biomed Pharmacother; 2021 Jan; 133():111081. PubMed ID: 33378977
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
[TBL] [Abstract][Full Text] [Related]
28. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
[TBL] [Abstract][Full Text] [Related]
30. Preventive and remedial application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension.
Zhang LL; Lu J; Li MT; Wang Q; Zeng XF
Int J Rheum Dis; 2016 Feb; 19(2):192-8. PubMed ID: 24612527
[TBL] [Abstract][Full Text] [Related]
31. Astragalus Polysaccharides Attenuate Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats.
Yuan LB; Hua CY; Gao S; Yin YL; Dai M; Meng HY; Li PP; Yang ZX; Hu QH
Am J Chin Med; 2017; 45(4):773-789. PubMed ID: 28521513
[TBL] [Abstract][Full Text] [Related]
32. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Leong ZP; Hikasa Y
Vascul Pharmacol; 2018 Nov; 110():31-41. PubMed ID: 30071297
[TBL] [Abstract][Full Text] [Related]
33. Novel assessment of haemodynamic kinetics with acute exercise in a rat model of pulmonary arterial hypertension.
Brown MB; Chingombe TJ; Zinn AB; Reddy JG; Novack RA; Cooney SA; Fisher AJ; Presson RG; Lahm T; Petrache I
Exp Physiol; 2015 Jun; 100(6):742-54. PubMed ID: 25867528
[TBL] [Abstract][Full Text] [Related]
34. Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates monocrotaline-induced pulmonary vascular remodeling.
Fu J; Chen YF; Zhao X; Creighton JR; Guo Y; Hage FG; Oparil S; Xing DD
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1539-47. PubMed ID: 24790141
[TBL] [Abstract][Full Text] [Related]
35. Intralipid prevents and rescues fatal pulmonary arterial hypertension and right ventricular failure in rats.
Umar S; Nadadur RD; Li J; Maltese F; Partownavid P; van der Laarse A; Eghbali M
Hypertension; 2011 Sep; 58(3):512-8. PubMed ID: 21747043
[TBL] [Abstract][Full Text] [Related]
36. 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
Lan TH; Chen XL; Wu YS; Qiu HL; Li JZ; Ruan XM; Xu DP; Lin DQ
Eur J Pharmacol; 2018 Jun; 829():102-111. PubMed ID: 29665366
[TBL] [Abstract][Full Text] [Related]
37. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
[TBL] [Abstract][Full Text] [Related]
38. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q
Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension.
Kimura S; Egashira K; Chen L; Nakano K; Iwata E; Miyagawa M; Tsujimoto H; Hara K; Morishita R; Sueishi K; Tominaga R; Sunagawa K
Hypertension; 2009 May; 53(5):877-83. PubMed ID: 19307469
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
